261 related articles for article (PubMed ID: 31445164)
21. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons.
Albrecht U; Sutcliffe JS; Cattanach BM; Beechey CV; Armstrong D; Eichele G; Beaudet AL
Nat Genet; 1997 Sep; 17(1):75-8. PubMed ID: 9288101
[TBL] [Abstract][Full Text] [Related]
22. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders.
LaSalle JM; Reiter LT; Chamberlain SJ
Epigenomics; 2015 Oct; 7(7):1213-28. PubMed ID: 26585570
[TBL] [Abstract][Full Text] [Related]
24. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome.
Su H; Fan W; Coskun PE; Vesa J; Gold JA; Jiang YH; Potluri P; Procaccio V; Acab A; Weiss JH; Wallace DC; Kimonis VE
Neurosci Lett; 2011 Jan; 487(2):129-33. PubMed ID: 19563863
[TBL] [Abstract][Full Text] [Related]
25. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.
Mabb AM; Judson MC; Zylka MJ; Philpot BD
Trends Neurosci; 2011 Jun; 34(6):293-303. PubMed ID: 21592595
[TBL] [Abstract][Full Text] [Related]
26. Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing.
Stanurova J; Neureiter A; Hiber M; de Oliveira Kessler H; Stolp K; Goetzke R; Klein D; Bankfalvi A; Klump H; Steenpass L
Sci Rep; 2016 Aug; 6():30792. PubMed ID: 27484051
[TBL] [Abstract][Full Text] [Related]
27. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
Greer PL; Hanayama R; Bloodgood BL; Mardinly AR; Lipton DM; Flavell SW; Kim TK; Griffith EC; Waldon Z; Maehr R; Ploegh HL; Chowdhury S; Worley PF; Steen J; Greenberg ME
Cell; 2010 Mar; 140(5):704-16. PubMed ID: 20211139
[TBL] [Abstract][Full Text] [Related]
28. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.
Gu B; Carstens KE; Judson MC; Dalton KA; Rougié M; Clark EP; Dudek SM; Philpot BD
J Clin Invest; 2019 Jan; 129(1):163-168. PubMed ID: 30352049
[TBL] [Abstract][Full Text] [Related]
29. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
[TBL] [Abstract][Full Text] [Related]
30. Angelman Syndrome Protein Ube3a Regulates Synaptic Growth and Endocytosis by Inhibiting BMP Signaling in Drosophila.
Li W; Yao A; Zhi H; Kaur K; Zhu YC; Jia M; Zhao H; Wang Q; Jin S; Zhao G; Xiong ZQ; Zhang YQ
PLoS Genet; 2016 May; 12(5):e1006062. PubMed ID: 27232889
[TBL] [Abstract][Full Text] [Related]
31. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations.
Bossuyt SNV; Punt AM; de Graaf IJ; van den Burg J; Williams MG; Heussler H; Elgersma Y; Distel B
Hum Mol Genet; 2021 Apr; 30(6):430-442. PubMed ID: 33607653
[TBL] [Abstract][Full Text] [Related]
32. The Angelman syndrome protein Ube3a/E6AP is required for Golgi acidification and surface protein sialylation.
Condon KH; Ho J; Robinson CG; Hanus C; Ehlers MD
J Neurosci; 2013 Feb; 33(9):3799-814. PubMed ID: 23447592
[TBL] [Abstract][Full Text] [Related]
33. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
34. Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.
Ramirez J; Lectez B; Osinalde N; Sivá M; Elu N; Aloria K; Procházková M; Perez C; Martínez-Hernández J; Barrio R; Šašková KG; Arizmendi JM; Mayor U
Hum Mol Genet; 2018 Jun; 27(11):1955-1971. PubMed ID: 29788202
[TBL] [Abstract][Full Text] [Related]
35. Azadiradione up-regulates the expression of parvalbumin and BDNF via Ube3a.
Jana S; Giri B; Das S; Manna A; Mandal SC; Ranjan Jana N
Gene; 2024 Mar; 897():148081. PubMed ID: 38101713
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Huang HS; Allen JA; Mabb AM; King IF; Miriyala J; Taylor-Blake B; Sciaky N; Dutton JW; Lee HM; Chen X; Jin J; Bridges AS; Zylka MJ; Roth BL; Philpot BD
Nature; 2011 Dec; 481(7380):185-9. PubMed ID: 22190039
[TBL] [Abstract][Full Text] [Related]
37. [From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].
Saitoh S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Jun; 33(3):127-30. PubMed ID: 25069246
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitin-protein ligase E3A (UBE3A) mediation of viral infection and human diseases.
Chaudhary P; Proulx J; Park IW
Virus Res; 2023 Oct; 335():199191. PubMed ID: 37541588
[TBL] [Abstract][Full Text] [Related]
39. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a.
Meng L; Person RE; Beaudet AL
Hum Mol Genet; 2012 Jul; 21(13):3001-12. PubMed ID: 22493002
[TBL] [Abstract][Full Text] [Related]
40. Hypersociability in the Angelman syndrome mouse model.
Stoppel DC; Anderson MP
Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
